Published in Drug Week, August 10th, 2007
Modafinil is indicated to improve wakefulness in patients with excessive sleepiness associated with narcolepsy. This new product is the bioequivalent to Provigil(R), a registered trademark of Cephalon, Inc. Provigil(R) tablets had U.S. sales of approximately $753 million for the 12-month period ended March 31, 2007, according to IMS Data.
Daniel H. Movens, Caraco's Chief Executive Officer, said, "We are...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.